Answers are grounded in this paper and cite their sources.
Triple chemotherapy improves efficacy in patients with advanced gastro-esophageal (GE) cancer. In a phase I dose-finding trial including 23 patients we established a recommended dose of triple chemotherapy with docetaxel (D), oxaliplatin (O), and capecitabine (X) (DOX). We found promising activity and here we present efficacy data from the succeeding phase II trial. Patients and Methods: All patients had histologically confirmed GE adenocarcinoma.
No takes yet. Share an insight, caveat, or question.
Tarpgaard et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: